CLASS II ONGOING Device recall · Reported 2 Aug 2023 · FDA Enforcement Report

QIAstat-Dx Respiratory Sars-CoV-2 Panel -US IVD qualitative recalled

Qiagen is recalling QIAstat-Dx Respiratory Sars-CoV-2 Panel -US IVD qualitative test intended for analyzing, distributed in 14 states. The recall was initiated on 19 May 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesGTIN 14053228038846 LOT Numbers: 175010704, 175011354 Exp. Date: 2023-10-06 and 2023-10-17
Quantity recalled386 kits

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2245-2023
FDA event ID
92609
Recalling firm
Qiagen, Hilden, N/A
Classification
Class II
Status
Ongoing
Recall initiated
19 May 2023
FDA classified
27 Jul 2023
Reported
2 Aug 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

19 May 2023Recall initiated by company
27 Jul 2023Classified by FDA+69 days
2 Aug 2023Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Identified a decreased performance reliability rate, Run abortions could cause delayed diagnosis since sample testing would have to be repeated

Product as listed by the FDA

QIAstat-Dx Respiratory SARS-CoV-2 Panel -US IVD qualitative test intended for analyzing nasopharyngeal swab (NPS) samples from patients suspected of respiratory infection for the presence of viral or bacterial nucleic acids REF 691223

Where it was distributed

DC, AL, CA, FL, GA, ME, NC, NY, OR, TX Foreign: DE, AE, AT, BE, BG, CH, CL, CY, CZ, DE, DK, ES, FI, FR, GB, GR, GT, HK, HU, ID, IN, IT, JO, MC, MU, MY, NL, NA, PL, PT, RO, SE, SK, TH, TN, TW, UY, YT, ZA

AlabamaCaliforniaDistrict of ColumbiaDelawareFloridaGeorgiaIdahoIndianaMaineNorth CarolinaNew YorkOregonTennesseeTexas

Questions about this recall

Why was it recalled?

Identified a decreased performance reliability rate, Run abortions could cause delayed diagnosis since sample testing would have to be repeated

Which lots are affected?

GTIN 14053228038846 LOT Numbers: 175010704, 175011354 Exp. Date: 2023-10-06 and 2023-10-17

Where was it sold?

DC, AL, CA, FL, GA, ME, NC, NY, OR, TX Foreign: DE, AE, AT, BE, BG, CH, CL, CY, CZ, DE, DK, ES, FI, FR, GB, GR, GT, HK, HU, ID, IN, IT, JO, MC, MU, MY, NL, NA, PL, PT, RO, SE, SK, TH, TN, TW, UY, YT, ZA

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 92609
ReportedClassRecallCompanyReasonWhere
CLASS IIQIAstat-Dx Respiratory Sars-CoV-2 Panel (V1 and V2, CE IVD recalledQiagenOther14 states

More recalls from Qiagen

All 6

Other CPAP & Ventilators recalls

All 552